drugset
drugset / Trial / NCT03708588

Chewed Versus Integral Pill of Ticagrelor

NCT03708588 ↗

Phase 4 Completed 112 enrolled Wake Forest University Health Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.

Timeline

Start
2018-09-19
Primary completion
2020-12-31
Completion
2021-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ticagrelor Small molecule 180 mg Other

Indications

No indication recorded.